Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (1310)	4/29/2002 9:35:17 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

Related Quote BTRN 3.50 0.00 delayed 20 mins - disclaimer Quote Data provided by Reuters ADVERTISEMENT Monday April 29, 9:08 am Eastern Time Press Release SOURCE: BioTransplant Kidney Transplant Patient in BioTransplant and Massachusetts General Hospital Study Nears Four Year Milestone Without Immune Suppressive Drugs CHARLESTOWN, Mass.--(BUSINESS WIRE)--April 29, 2002--BioTransplant (Nasdaq: BTRN - news) - Latest Patient Enrolled in a New Trial Funded By Immune Tolerance Network (ITN) Passes Eight Month Milestone; Additional Trial in Patients Without Cancer To Open - BioTransplant (Nasdaq: BTRN - news) today announced the latest results of a study involving a prototype of the company's AlloMune(TM) System for kidney transplants in multiple myeloma patients, conducted in collaboration with researchers from Massachusetts General Hospital (MGH) and Harvard Medical School. The first patient in the study has been kept alive and free of cancer for almost four years without immunosuppressive drugs to prevent rejection of the kidney. The most recent patient in the study has remained alive for eight months following a kidney transplant, is in remission, and is currently on low levels of cyclosporin for the treatment of mild graft versus host disease; one other patient has been kept alive and is in remission for 18 months so far, without chronic immunosuppressive